Sign in Subscribe
BioMed

🧬 BioMed Pulse · 2026-07-14 02:02 UTC

BIOMED PULSE

Monday, 14 July 2026 | Your daily briefing on longevity, viruses, and new cures

⚡ TL;DR

The Bundibugyo virus Ebola outbreak in DRC and Uganda has now reached 1,460 confirmed cases and 452 deaths as of 1 July, making it the dominant global health emergency of 2026. The overall mood is guarded: a historic treatment trial just opened enrollment in DRC, offering cautious hope, but case counts continue climbing.

🦠 OUTBREAKS & VIRUSES

EBOLA BUNDIBUGYO VIRUS - DRC AND UGANDA (PHEIC)

  • As of 1 July 2026, the DRC has confirmed 1,460 Bundibugyo virus disease (BVD) cases and 452 deaths, with cross-border transmission ongoing in Uganda. [1]
  • WHO declared BVD a Public Health Emergency of International Concern on 17 May 2026; the IHR Emergency Committee confirmed it does not yet meet criteria for a pandemic emergency. [2] [3]
  • Africa CDC and WHO launched a joint continental Ebola response plan on 5 June 2026 seeking US$518 million to support African countries. [4]
  • WHO issued its first comprehensive clinical management guidelines for filovirus disease, covering all Ebola types and Marburg, on 17 June 2026. [5]
  • On 2 July 2026, WHO added the first molecular diagnostic test for Bundibugyo virus to its Emergency Use Listing, identifying the virus via genetic material in blood samples. [6]
  • The PARTNERS clinical trial opened patient enrollment in DRC on 2 July 2026 to evaluate the first potential treatments specifically for BVD. [7]
  • CDC confirmed the DRC-Uganda Ebola outbreak statement as of 10 July 2026 and continues airport screening at Washington-Dulles and Atlanta Hartsfield-Jackson. [8] [9] [10]

ANDES HANTAVIRUS - M/V HONDIUS CRUISE SHIP, MULTI-COUNTRY

  • The fifth WHO Disease Outbreak News report (2 July 2026) on the Andes hantavirus outbreak linked to cruise ship M/V Hondius confirmed additional cases since the previous update of 28 May.
  • The outbreak was first reported to WHO on 2 May 2026 with seven cases (two laboratory confirmed) aboard the ship carrying 147 passengers and crew.
  • CDC has provided multiple briefing transcripts on its hantavirus response through late June 2026.

NIPAH VIRUS - INDIA (KERALA)

  • On 11 June 2026, Kerala State confirmed one laboratory-confirmed Nipah virus case in Kozhikode district, an adult male with neurological symptoms hospitalized on 10 June.
  • Earlier in 2026, WHO recorded two healthcare worker cases in West Bengal (January) and one case in Bangladesh's Rajshahi Division (February).

MPOX - RECOMBINANT STRAIN

  • WHO reported a recombinant monkeypox virus strain combining clade Ib and clade IIb genomic elements in February 2026; recombination occurs when two related viruses co-infect one individual.

AVIAN INFLUENZA H9N2 - ITALY

  • Italy notified WHO in March 2026 of one human H9N2 case in an adult male returning from Senegal, confirmed by next-generation sequencing.

MEASLES - BANGLADESH

  • Bangladesh notified WHO of a nationwide surge in April 2026, with 19,161 suspected cases and 2,897 laboratory-confirmed cases across 58 of 64 districts.

YELLOW FEVER - GLOBAL

  • From 1 January to 26 May 2026, six countries reported 79 human infections; transmission from the 2025 Americas surge carried into 2026.

WEST NILE VIRUS - UNITED STATES

  • CDC reported an early and record-breaking West Nile season as of 1 July 2026, urging mosquito bite prevention over the Independence Day holiday weekend.

TRACHOMA ELIMINATION - EL SALVADOR

  • WHO validated El Salvador on 13 July 2026 as having eliminated trachoma as a public health problem; trachoma is the world's leading infectious cause of preventable blindness.

🧬 LONGEVITY & AGING

NAD+ RESTORATION FOR AGED BONE REPAIR

  • A new study in Bioactive Materials (published 27 June 2026) describes a senescent metabolism-modulating hierarchical scaffold that restores NAD+ homeostasis and redox balance, promoting bone repair in aged tissue.
  • NAD+ decline is a well-established hallmark of cellular aging; restoring it in scaffolds offers a localized strategy that bypasses systemic side effects of oral NAD+ precursors.

KAEMPFEROL FROM MORINGA AND LONGEVITY IN DROSOPHILA

  • Research published in Toxicology Reports (25 June 2026) found that kaempferol extracted from Moringa oleifera increases lifespan and reduces efavirenz-induced functional senescence in Drosophila melanogaster, the standard invertebrate aging model.
  • The finding is notable given simultaneous CDC and WHO alerts about Salmonella contamination in moringa leaf supplement products.

DELIRIUM AS A MISSING LINK BETWEEN INFECTION AND DEMENTIA

  • Two companion papers in Lancet Healthy Longevity propose that delirium during severe infection is a mechanistic bridge to subsequent dementia, suggesting acute inflammatory episodes may accelerate neurodegeneration.
  • Authors include Sipilä, Kivimäki, Penfold, Jiwaji, and MacLullich; the hypothesis points to delirium prevention as a potentially modifiable dementia risk factor.

PREPARING FOR A DEMENTIA PREVENTION ERA

  • A Lancet Healthy Longevity commentary by Beeri and Gu (published 2026) argues that dementia prevention trials must account for real-world social and structural determinants of brain aging, not just biological targets.

TAU-INDUCED NUCLEAR MECHANOTRANSDUCTION IN NEURONS

  • A study in Nucleus (7 July 2026) by Sohn et al. found that the mechanically sensitive nuclear envelope protein emerin is elevated in tau pathology, linking nuclear mechanotransduction to cytoskeletal remodeling implicated in Alzheimer disease and other tauopathies.

HYPERTENSION AND FRAILTY IN OLDER ADULTS - INDIA

  • A letter in Blood Pressure (7 July 2026) highlights associations between hypertension and frailty among middle-aged and older adults, drawing on data from the Longitudinal Ageing Study in India, underscoring cardiovascular risk management as an anti-frailty strategy.

METABOLIC LIVER DISEASE AND TOBACCO BURDEN

  • A Europe PMC study (3 July 2026) modeled the global burden of metabolic dysfunction-associated steatotic liver disease attributable to tobacco from 1990 to 2023, projecting trends to 2038, identifying tobacco as a major and underappreciated driver of liver aging.

BLOOD FLOW RESTRICTION TRAINING, STEM CELLS, AND AGING MUSCLE

  • A 3-year ClinicalTrials.gov study (NCT07569627) is measuring the effect of blood flow restriction training on skeletal muscle stem cells and immune cells, with additional arms testing beta-NMN (a vitamin B3 precursor and NAD+ precursor) and antioxidants on the same outcomes.

FIBROSIS DETECTION WITH 18F-FAPI-74 PET/CT

  • Trial NCT07613099 is using 18F-FAPI-74 PET/CT imaging to detect fibroblast activation protein in early-stage cardiac and pulmonary fibrosis before visible scar tissue forms, targeting a window for intervention.

GEOGRAPHIC ATROPHY IN AGE-RELATED MACULAR DEGENERATION

  • AbbVie is sponsoring a Phase 1 trial (NCT07160179) of intravitreal ABBV-6628 for geographic atrophy secondary to AMD, assessing safety and pharmacokinetics.
  • A separate observational study (NCT07144137) in adults aged 55 and older is quantifying short-term GA progression to build benchmarks for future AMD trials.

MEDICAL AND SOCIAL DETERMINANTS OF HEALTHY LONGEVITY

  • A comprehensive analysis published in Problemy Sotsialnoy Gigieny (authors Amonova, Osmonova, Sodikova, Ananchenkova) reviews prevention strategies targeting social, economic, and healthcare system factors that drive healthy longevity outcomes.

💊 NEW CURES & APPROVALS

TRUTAKNA (ATACIEPT-VYMJ) - VERA THERAPEUTICS

  • FDA recorded an original approval action (ORIG AP) for Trutakna, active ingredient ataciept-VYMJ (BLA761486), sponsored by Vera Therapeutics Inc.; ataciept is a fusion protein that blocks both BAFF and APRIL, two B-cell survival factors implicated in autoimmune and kidney diseases including IgA nephropathy.

RINVOQ LQ (UPADACITINIB) - ABBVIE

  • A supplemental approval (SUPPL AP) was recorded for Rinvoq LQ (NDA218347), AbbVie's liquid formulation of the JAK1-selective inhibitor upadacitinib, extending access to patients who cannot swallow tablets.

RYALTRIS (MOMETASONE FUROATE / OLOPATADINE HYDROCHLORIDE) - GLENMARK SPECIALTY

  • A supplemental approval (SUPPL AP) was recorded for Ryaltris (NDA211746), Glenmark's fixed-dose intranasal combination of a corticosteroid and an antihistamine for allergic rhinitis.

INBRIJA (LEVODOPA INHALATION POWDER) - MERZ

  • A supplemental approval (SUPPL AP) was recorded for Inbrija (NDA209184), Merz's inhaled levodopa for off episodes in Parkinson disease patients on a carbidopa/levodopa regimen.

VARENICLINE TARTRATE - SOMERSET THERAPEUTICS

  • An original approval (ORIG AP) was recorded for a generic varenicline tartrate formulation (ANDA219382) by Somerset Therapeutics LLC, adding generic supply for smoking cessation treatment.

🧪 CLINICAL TRIALS

PARTNERS TRIAL - BUNDIBUGYO VIRUS TREATMENTS, DRC

  • Patient enrollment opened 2 July 2026 in the DRC for the PARTNERS clinical trial, described by WHO as a major international effort to evaluate the first-ever potential treatments for Bundibugyo virus disease. [7]

AI VERSUS TIRZEPATIDE FOR OBESITY AND TYPE 2 DIABETES (NCT07697391)

  • A multicenter RCT registered 13 July 2026 will compare an AI-assisted intensive lifestyle intervention against tirzepatide (the dual GIP/GLP-1 agonist) and standard care in adults with obesity and newly diagnosed type 2 diabetes; registered 13 July 2026.

BFR TRAINING WITH BETA-NMN FOR AGING MUSCLE (NCT07569627)

  • A 3-year Norwegian trial will assess blood flow restriction training plus beta-NMN (a NAD+ precursor) effects on skeletal muscle stem cells and immune cells in human participants, directly targeting muscle aging biology.

ABBV-6628 FOR GEOGRAPHIC ATROPHY / DRY AMD (NCT07160179)

  • AbbVie Phase 1 trial evaluating intravitreal ABBV-6628 safety and pharmacokinetics in adults with geographic atrophy secondary to age-related macular degeneration; registered on ClinicalTrials.gov.

IL-15 SUPERAGONIST N-803 WITH VACCINE FOR PROSTATE CANCER (NCT07686380)

  • NIH-sponsored trial testing N-803 (an IL-15 superagonist) alone or combined with ETBX-071 vaccine in men with biochemically recurrent prostate cancer after stereotactic body radiation, targeting 30,000-50,000 new BCR cases per year.

BPL-1357 BROAD INFLUENZA VACCINE CHALLENGE STUDY (NCT07215858)

  • Trial NCT07215858 is testing BPL-1357, an inactivated whole-virion broad-spectrum influenza candidate, in an H1N1 human challenge model, with pandemic preparedness as the stated rationale given 3-5 million annual flu cases globally.

FUYANG JIEDU GRANULES PLUS ART FOR HIV IMMUNE NON-RESPONDERS (NCT07698548)

  • A pragmatic RCT registered 13 July 2026 will test whether the traditional Chinese medicine formulation Fuyang Jiedu Granules combined with antiretroviral therapy improves immune reconstitution in HIV patients who have failed to recover CD4 counts despite virologic suppression.

MAP-HEART HEART FAILURE PHENOTYPING STUDY (NCT06280820)

  • The Multi-Scale Analysis of Phenotypes in Heart Failure study is comparing blood and tissue biomarkers in the 6.5 million US adults living with heart failure to understand how the disease develops and diverges by subtype.

📢 PUBLIC HEALTH

CANCER CASES PROJECTED TO NEARLY DOUBLE BY 2050

  • WHO reported on 8 July 2026 that an estimated 20.6 million new cancer cases and nearly 10 million deaths occur annually, with new cases projected to nearly double by 2050; WHO called for urgent action.

WHO CANCER TOLL TODAY

  • WHO data indicate cancer currently claims more than 26,000 lives every day worldwide, with the financial and emotional toll described as a global crisis.

SALMONELLA IN MORINGA LEAF PRODUCTS - ONGOING US ALERT

  • As of late May 2026, CDC and FDA continued issuing alerts about a growing number of Salmonella illnesses and outbreaks linked to moringa leaf supplement products across multiple states; an extensively drug-resistant strain was documented in February 2026.

E. COLI IN FROZEN BLUEBERRIES - US RECALL

  • CDC issued a food safety alert on 7 July 2026 warning consumers not to eat recalled frozen blueberries linked to an E. coli outbreak.

LISTERIA IN REQUESÓN/SOFT RICOTTA CHEESE

  • CDC warned on 5 June 2026 of a Listeria monocytogenes outbreak linked to requesón/soft ricotta cheese.

UNSAFE FOOD KILLS 1.5 MILLION ANNUALLY - WHO

  • New WHO estimates released 4 June 2026 found that unsafe food causes 866 million illnesses and 1.5 million deaths annually; children under five face nearly three times the illness risk of older age groups.

WHO PANDEMIC AGREEMENT - PATHOGEN ACCESS ANNEX

  • An open letter dated 15 June 2026 from WHO to G7, G20, and BRICS leaders urged finalizing the Pathogen Access and Benefit Sharing annex of the WHO Pandemic Agreement, calling it unfinished essential global health infrastructure.

NICOTINE POUCHES TARGETING YOUTH - WHO WARNING

  • WHO warned on 15 May 2026 of rapidly surging sales of nicotine pouches with aggressive youth-targeted marketing and called on governments to implement strong regulatory measures.

PNEUMOCOCCAL VACCINATION AGE LOWERED TO 50 IN THE US

  • CDC Director endorsed the ACIP recommendation in October 2024 lowering the age for pneumococcal vaccination from 65 to 50 years, expanding protection against bacterial pneumonia to a broader adult population.

This briefing is for informational purposes only and does not constitute medical advice. Consult a qualified healthcare professional for personal health decisions.

📎 Sources

  1. Ebola disease caused by Bundibugyo virus, Democratic Republic … — WHO Disease Outbreak News
  2. Epidemic of Ebola Disease caused by Bundibugyo virus in the De… — WHO News
  3. First meeting of the IHR Emergency Committee regarding the epi… — WHO News
  4. Africa CDC and WHO launch joint continental Ebola response plan — WHO News
  5. WHO issues comprehensive guidelines on filovirus disease, incl… — WHO News
  6. WHO adds first diagnostic test for Ebola Bundibugyo virus to i… — WHO News
  7. Patient enrolment begins in a scientific trial to identify the… — WHO News
  8. CDC Statement on Ebola Outbreak in the Democratic Republic of … — CDC Newsroom
  9. Enhanced Ebola Airport Screening Begins at Washington-Dulles I… — CDC Newsroom
  10. Enhanced Ebola Airport Screening Expands to Atlanta — CDC Newsroom

Curated from official sources — WHO/CDC/ECDC/openFDA/ClinicalTrials.gov/Europe PMC. Informational only — not medical advice.
Serial 20260714-02-v27 · 2026-07-14 02:02 UTC · pulse.uzylab.com

Read next